Sutro Biopharma, Inc. reported financial results for the quarter ended June 30, 2026, revealing revenue of $9.8 million and a net loss of $38.5 million. The company holds $164.3 million in cash, cash equivalents, and marketable securities, providing an expected operational runway into at least the second quarter of 2028. Clinically, Sutro provided early data from its Phase 1 study of STRO-004, a Tissue Factor-targeting ADC, noting confirmed partial responses across pancreatic, head and neck, and non-small cell lung cancers with favorable tolerability. The company is currently optimizing the dose between 4 and 5 mg/kg for STRO-004. Additionally, Sutro announced that its next-generation integrin β6-targeting ADC, STRO-006, is on track to enter Phase 1 clinical trials in the third quarter of 2026. The company operates as a clinical-stage biotechnology firm pioneering site-specific and novel-format antibody-drug conjugates for oncology.

Sutro Biopharma, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026, where stockholders-approved the election of three Class II directors and the appointment of Ernst & Young LLP as the company's independent registered public accounting firm. Additionally, the meeting held a voting on a non-binding advisory basis, voting to approve the compensation of the company's named executive officers.